Skip to content

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account?

Top 3 dividend stocks to buy for 2026

Top 3 dividend stocks to buy for 2026

Holding dividend stocks remains one of the most effective long-term strategies, with companies that pay a regular dividend often being profitable and well-positioned for future growth, even during economic downturns

What follows are the top 3 dividend stocks to buy right now and hold in 2026.

1. Coca-Cola (KO)

Coca-Cola dividends. Source: Dividend.com

Warren Buffett’s 25+ year commitment to Coca-Cola (NYSE: KO) is a testament to the company’s long-term value. Namely, his firm, Berkshire Hathaway (NYSE: BRK), owns 400 million shares and is set to receive $204 million in dividends in July.

As a Dividend King, Coca-Cola recently raised its dividend for the 63rd consecutive year, now paying an annualized dividend of $2.04 per share. 

With a sustainable payout ratio of 77.42%, the dividend appears secure, and the company expects 5–6% organic revenue growth, continuing to outperform competitors like Pepsi (NASDAQ: PEP).

2. Johnson & Johnson (JNJ)

Johnson & Johnson dividends. Source: Dividend.com

Johnson & Johnson (NYSE: JNJ), another Dividend King, has likewise increased its dividend by 63 consecutive years. 

Johnson & Johnson maintains a diverse portfolio spanning oncology, neuroscience, and immunology, generating over $1 billion in annual sales. For the last quarter, the company reported a 2.4% increase in revenue year-over-year (YoY), and earnings per share (EPS) came in at $4.54.

Johnson & Johnson currently boasts a dividend yield of about 3.37%, which is higher than the 1.59% average of the biotech and 2.31% of the pharmaceutical sector.

3. Pfizer (PFE)

Pfizer dividends. Source: Dividend.com

Another pharmaceutical giant, Pfizer (NYSE: PFE) gained prominence during the COVID-19 pandemic, and although its vaccine revenues are declining, the company is slowly upgrading its drug pipeline and forging some strategic partnerships.

Indeed, the company has 108 candidates in the pipeline with 30 of them already in Phase 3.

Currently, Pfizer has a dividend yield of over 7.37%, which makes it one of the most attractive companies among large-cap healthcare stocks. 

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Latest posts

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Stocks

Trade, Swap & Stake Crypto on Uphold

Buy, sell, and swap crypto. Stake crypto, earn rewards and securely manage 300+ assets—all in one trusted platform. Terms apply. Capital at risk.

Get Started

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.